Use and Impact of Cardiac Medication During Pregnancy

Annemien E van den Bosch; Titia PE Ruys; Jolien W Roos-Hesselink


Future Cardiol. 2015;11(1):89-100. 

In This Article

Conclusion & Future Perspective

Pregnancy is a hemodynamic burden and may reveal latent underlying heart disease and/or trigger the new onset of maternal heart disease. Morbidity and mortality is increasing during pregnancy and peripartum due to cardiovascular disease, and this is will further increase as the population of women with congenital of acquired heart disease is increasing. A concern is the increasing prevalence of women with acquired heart disease due to the increasing age of first pregnancy and the increasing prevalence of cardiovascular risk factors, such as obesity and diabetes. These women need careful preconception counseling, as well as adequate management during pregnancy. Women and their care providers must weigh the risks and benefits of medication during pregnancy. The efficacy of drugs used during pregnancy can be altered by pregnancy and attention should be paid to the adjustment of doses and possible effects on the fetus. New cardiovascular drugs and devices will become available and need to be used with caution regarding their risks and benefits in the pregnant population. New treatments should be implemented slowly after maternal and fetal risks have been evaluated. Most cardiac conditions needing medical treatment will be treated with extensively studied medications that are known to be reasonably safe and effective in pregnancy.